CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese

Figures & data

Figure 1 Oral clearance of gliclazide in different CYP2C19 genotype groups.

Abbreviations: EM, extensive metaboliser; IM, intermediate metaboliser; PM, poor metaboliser.

Table 1 Comparison of Pharmacokinetic Parameters of Gliclazide Among Different CYP2C19 Genotype Groups

Parameters	Genotype Group			One Way ANOVA	Multiple Comparisons p value
	EM n=4	IM n=7	PM N=4	p =	EM vs IM	EM vs PM	IM vs PM
Tmax (hr)	3.13(1.03)	3.29(0.82)	3.88(0.95)	0.51	N/A	N/A	N/A
Cmax (ng/mL)	4.48(1.44)	4.49(0.67)	4.75(0.44)	0.89	N/A	N/A	N/A
AUC0-last (ng.h/mL)	56.3(18.8)	65.8(14.4)	106.2(14.4)	0.001	0.99	0.003	0.002
AUC0-inf (ng.h/mL)	57.0(19.0)	67.8(15.8)	117.3(17.7)	<0.001	0.95	0.002	0.001
t1/2 (hr)	11.5(1.0)	13.6(2.0)	20.6(1.88)	<0.001	0.24	<0.0001	<0.001
CL/F (mL/min/kg)	1.52(0.47)	1.22(0.22)	0.70(0.12)	0.005	0.35	0.037	0.004

Note: Data mean (SD).

Abbreviations: EM, extensive metaboliser; IM, intermediate metaboliser; PM, poor metaboliser; T_max, time to peak plasma concentration; C_max, peak plasma concentration; AUC_last, area under concentration–time curve to last measurement; AUC_inf, area under concentration–time curve to infinity; t_1/2, termination elimination half-life; CL/F, apparent oral clearance.